Stocks that Neil Woodford is Buying and Selling


Neil Woodford is arguably the best British fund manager of this generation. In his last job managing the Invesco Perpetual fund he managed to deliver an average of 9% a year over 25 years – a remarkable feat. Neil Woodford left his job at Invesco to start up his own fund company. His Woodford Equity Income fund which started operating in June 2014 has delivered a staggering return of 19.6% for the full year. In comparison, the average UK equity company had returned 9.3%, while the FTSE All Share index was up 6.5%.

With Neil Woodford, his reputation is backed up by strong annual returns year after year as seen above. So the question is, how do you get Woodford like returns? One way is to invest directly in his Woodford Equity Income fund or you can buy into his newly launched Woodford Patient Capital Trust (although the price for this is currently high as it is trading at a substantial premium).
Alternatively, you can directly purchase the stock Neil Woodford is buying thus bypassing the annual management fee. (I will soon be writing an article to show how fees compound over time and cost the investor a substantial chunk of their returns).

Neil Woodford buys in May (Equity Income Fund)

First, we look at the companies Neil Woodford has increased his stake the most last month. These are the stocks Woodford paid particular attention to and bought in May through the equity income fund:

  1. Homeserve—Increased his stake in the company by 58%.
  2. Legal & General—increased his stake in the company by 17%
  3. Centrica— Increased his stake in the company by 15%. A whopping 150% increased from the previous month.
  4. Utilitywise— Increased his stake in the company by 12%
  5. Imperial Tobacco— Increased his stake in the company by 11%
  6. NetScientific— Increased his stake in the company by 9%
  7. BTG— Increased his stake in the company by 9%
  8. Reynolds American— Increased his stake in the company by 8%
  9. Redde— Increased his stake in the company by 6%
  10. Mercia Technologies— Increased his stake in the company by 5%
  11. Midatech Pharma— Increased his stake in the company by 5%
  12. Allied Minds— Increased his stake in the company by 4%
  13. BAE Systems— Increased his stake in the company by 4%
  14. Next— Increased his stake in the company by 4%
  15. Game Digital— Increased his stake in the company by 4%
  16. G4S— Increased his stake in the company by 4%
  17. e-Therapeutics— Increased his stake in the company by 4%
  18. 4D Pharma— Increased his stake in the company by 3%

The above calculations are from “
http://dividend-drive.blogspot.co.uk/2015/06/the-maestros-movers-neil-woodfords-big.html” Have a look at the website, it has some really good articles.

 

Neil Woodford sells in May (Equity Income Fund)

Below is a list of companies Neil Woodford has decreased his stake the most last month. These are the stocks Woodford paid particular attention to and sold in May through the equity income fund:

Below is a list of stocks that are in Neil Woodford’s Portfolio; either in the Woodford Equity Income Fund or his Woodford Patient Capital Trust.

  1. Sanofi— sold 100% of his stake in this pharmaceuticals company. Although Woodofrd has sold his entire stake in this company, he still believes it to be a good one. Woodford states that the only reason he this holding is because there are other companies that offer better value at present.
  2. Roche— sold 12% of his stake in this pharmaceuticals company.
  3. AA— sold 12% of his stake in this company.
  4. HaloSource— sold 9% of his stake in this company.
  5. Amlin— sold 7% of his stake in this company.
  6. RM2 International— sold 7% of his stake in this company.
  7. Capita— sold 6% of his stake in this company.
  8. Zegona— sold 5% of his stake in this company.
  9. PayPoint— sold 3% of his stake in this company.
  10. Babcock International— sold 3% of his stake in this company

The above calculations are from “
http://dividend-drive.blogspot.co.uk/2015/06/the-maestros-movers-neil-woodfords-big.html” Have a look at the website, it has some really good articles.

 

List of stocks Neil Woodford has been Buying over time:

Below is a list of notable companies that Neil Woodford has been buying over the past year

  • Alkermis – US biotech firm Alkermes was particularly strong, after two of its drugs – designed to treat clinical depression and schizophrenia – produced positive results in clinical trials. We view these positive trial results as potentially very significant developments and further evidence of the strength of Alkermes’ pipeline.’
  • AstraZeneca – This is perhaps Woodford favourite stock. Woodford has been buying stocks in this company ever since inception of his equity income fund and added a 13% stake over current holdings in May. Woodford is a big fan of healthcare stocks and owns several healthcare companies in his portfolio.
  • British American Tobacco – Woodford loves owning Tobacco stocks as seen by his investment in British American Tobacco, Imperial Tobacco Group and Reynolds America. Woodford says the following about Tobacco stocks : ’One of the most dependable sources of dividend income for the equity investor is the tobacco sector, which features prominently in the portfolio. Over the past 25 years, the tobacco sector has an unsurpassed track record of delivering superior long-term total returns, based on attractive starting yields and consistent, sustainable dividend growth
  • BT Group – Woodford has been consistently adding to this large blue-chip steady dividend paying stock over the past year.
  • Crystal Amber  – Crystal Amber is an activist fund that buys stakes into other companies and forces change through either management or strategy shakeup.
    Woodford has a 10.1% stake in this company having increased his stake in January 2015. Crystal Amber, which is currently sitting on 1.9% discount, has delivered a total share price return of 85.3% over the last three years versus a 68% rise in the FTSE 250 excluding investment trusts. Its net asset value has risen has returned 51.5% over the same period.
  • GlaxoSmithKline – Woodford believes this pharmaceutical firm is grossly undervalued and has increased his stake in the company by 29% for his equity income fund
    His old fund at Invesco Perpetual  also belives GSK is grossly undervalued and the fund has increased its stake in the company by 27%
  • Imperial Tobacco Group – Another Tobacco stock Woodford loves. See British American Tobacco above.
  • Reynolds America – Another Tobacco stock Woodford loves. See British American Tobacco above.

 

List of stocks Neil Woodford has been Selling over time:

Below is a list of notable companies that Neil Woodford has been selling over the past year

  • HSBC –Woodford described HSBC as “a very different beast” to the UK’s other banks, being a “conservatively-managed, well-capitalised business with a good spread of international assets”. And he found the valuation attractive: “trading at around or even below its book value and its yield is also appealing

However, three months after the launch of his new fund, Woodford ditched his HSBC holding, saying that he was becoming concerned that fines “are increasingly being sized on a bank’s ability to pay, rather than on the extent of the transgression”. He felt that “fine inflation” was an unquantifiable risk that could potentially hamper HSBC’s ability to grow its dividend

  • Reckit bensicker – Consumer goods group Reckitt Benckiser is a stock Woodford had held in his portfolios for more than a decade, the attraction being “a great business with a very strong management team and an excellent product line-up”

In September last year Woodford sold his stake in Reckit benckiser and stated“Such a high quality business deserves a high market rating but the shares have recently become too expensive to continue to justify their position in the portfolio”.

  • Smith & nephew – Medical devices firm Smith & Nephew is another holding Woodford disposed of purely on valuation grounds. The shares soared on bid speculation last December, and reached a peak of around £12 in January when Woodford sold. The P/E, based on forecast earnings for the December year end, was 21 and the dividend yield was 1.7%.

Woodford’s team stated: “Clearly, if a bid were to materialise, it could lift the share price higher still but we believe other opportunities now offer greater long-term income potential

 

List of companies in Woodford Patient Capital Trust

The companies Woodford has so far bought in the WPCT are

  • AJ Bell – Through wood ford patient capital trust, he bought an £8m stake
    AJ Bell is a platform that allows individual investors to hold funds from a wide variety of asset management groups, as well as securities such as shares and bonds, within a single Isa or self-managed pension, and to change their portfolios at the touch of a button. The sector is dominated by Hargreaves Lansdown, a member of the FTSE 100.
  • Giga clear
  • Kymab
  • SciFluor
  • Sphere Medical – Owns a 17 % stake in the company. Bought shares at a price of 16.00
  • Verseon

 

The above are the trades Neil Woodford is currently conducting in his portfolio. Why do you research the above companies an start investing like Neil Woodford himself.

 

Please like & share: